CF PharmTech, Inc. (02652) issued a Next Day Disclosure Return dated 16 February 2026, outlining repurchase activity and the resulting changes in its share capital structure.

On 16 February 2026, the company repurchased 73,000 H shares at prices ranging from HKD 35.30 to HKD 36.60, totaling HKD 2.64 million. The repurchased shares represent approximately 0.0242% of the outstanding ordinary shares; these shares are held as treasury shares, bringing total treasury shares to 355,000 and leaving 301.87 million shares in issue (excluding treasury shares).

As of the same date, the total number of issued shares remained 302.22 million. The initial repurchase mandate was authorized on 16 December 2025, permitting up to 30.22 million shares to be acquired. The cumulative repurchase count has reached 355,000 shares—equating to 0.12% of the issuer’s outstanding shares at the mandate date—while a moratorium on share issuance or treasury share sales is in effect until 18 March 2026.